Last reviewed · How we verify
NCT03842904: TRIFLOW
A Study Comparing the Effects of Trimbow to Fostair in COPD
Phase 4 trial testing Trimbow pMDI in Chronic Obstructive Pulmonary Disease (COPD) in 23 participants. Completed in 6 August 2019.
30 July 2019
Quick facts
| Lead sponsor | Medicines Evaluation Unit Ltd |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 13 December 2018 |
| Primary completion | 30 July 2019 |
| Estimated completion | 6 August 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Trimbow pMDI — full drug profile →
- Fostair pMDI — full drug profile →
Conditions studied
- Chronic Obstructive Pulmonary Disease (COPD) — all drugs for Chronic Obstructive Pulmonary Disease (COPD) →
Sponsor
Medicines Evaluation Unit Ltd — full company profile →
Who can join
Adults 40 to 75, any sex, with Chronic Obstructive Pulmonary Disease (COPD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J, Panainte C, Khan N, Singh D. · · 2020 · cited 12× · PMID 33298062 · DOI 10.1186/s12931-020-01589-5
Verify or expand the search:
- PubMed search for NCT03842904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Obstructive Pulmonary Disease (COPD)
Currently open trials in the same condition.
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07355868 — Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy · EARLY_PHASE1 · recruiting
- NCT06892210 — Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) · Phase 4 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07519603 — Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03842904 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medicines Evaluation Unit Ltd
- Last refreshed: 27 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03842904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing